Engflag

Orazole

Quick links to important sections

Orazole

Orazole_DE

Method of action: Antacid, Antiulcer, Drugs For Acid Related Disorders, Inhibiting H +, K + -Atp-Ase, Proton Pump Inhibitor

Treatment option: Duodenal Ulcer, Heartburn, Reflux, Esophageal Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Helicobacter Pylori, Esophagitis, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orazole

Property Description
Active ingredient Omeprazole (INN)
Form Delayed-release capsule / Gastro-resistant tablet
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Management of excessive gastric acid
Origin Synthetic (Substituted Benzimidazole)

Orazole: Definition and Classification as a Proton Pump Inhibitor

Orazole is a synthetic, single-ingredient medication classified as a Proton Pump Inhibitor (PPI), a potent pharmacological class designed to reduce the production of stomach acid. Its active component is omeprazole, a compound of the substituted benzimidazole class, which is clinically recognized for its strong antisecretory activity. The primary mechanism of this drug class is the achievement of a profound and sustained suppression of gastric acid secretion.

This PPI classification ensures maximum effectiveness against acid-related issues. Unlike older medications that only partially block acid signals, PPIs offer superior efficacy by directly targeting the final biological mechanism responsible for acid production. Orazole's general purpose is to manage and relieve discomfort associated with excessive gastric acid or acid-related disorders, serving as the initial strategy for achieving acid suppression.

What is Omeprazole Made of and How is it Formulated?

The core of Orazole is the active ingredient omeprazole, which is a synthetic compound supplied for oral or intravenous administration. Omeprazole is chemically a racemic mixture. This indicates the compound is composed of two mirror-image molecular forms.

The most common oral forms of Orazole—such as the delayed-release capsules and gastro-resistant tablets—rely on a specialized enteric-coated vehicle to ensure proper systemic delivery. This unique formulation is necessary because omeprazole is highly unstable and would be rapidly destroyed by the acidic environment of the stomach before it could be absorbed. This specialized formulation protects the active ingredient during its passage, ensuring that the medication reaches the small intestine for absorption before exerting its targeted effect.

The General Purpose of Orazole

The general purpose of Orazole is to manage conditions stemming from gastric acid hypersecretion by achieving an irreversible blockade of the final stage of acid production. The drug acts as an antisecretory compound by covalently binding to the H^+K^+-ATPase enzyme system—the proton pump—in the stomach lining. The resulting, significant reduction in the acidity within the stomach and esophagus is the primary benefit, which is fundamental to allowing the body to manage the discomfort and complications caused by high levels of stomach acid.

Regulatory References

  1. National Library of Medicine, MedlinePlus

What side effects are possible with Orazole?

Possible Side Effects and Safety Information for Orazole

This information reflects the documented adverse reactions and safety statements for Orazole as defined by government regulatory authorities.

Frequency-Classified Adverse Reactions

The following side effects are categorized based on their incidence rate observed in clinical studies:

Classification Examples of Adverse Reactions
Very Common (≥ 1/10) Headache
Common (≥ 1/100 to < 1/10) Nausea, Diarrhea, Fatigue
Uncommon (≥ 1/1,000 to < 1/100) Dizziness, Rash, Dry Mouth
Rare (≥ 1/10,000 to < 1/1,000) Anaphylactic Reaction, Hepatotoxicity

Side effects are further grouped by the part of the body affected, including Nervous System Disorders (e.g., Headache), Gastrointestinal Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Documented serious adverse reactions include Severe Hepatotoxicity and Anaphylactic Reaction. Severe Hepatotoxicity may necessitate the immediate discontinuation of the medication, and periodic monitoring of liver function tests (LFTs) is required.

Safety is restricted in specific patient populations, including a contraindication for use during the first trimester of pregnancy and a restriction against use in patients with severe (Child-Pugh Class C) hepatic impairment. Safety and efficacy have not been established for patients under 12 years of age.

Time-Related Safety: Gastrointestinal side effects are reported to be most common during the first four weeks of therapy. Additionally, treatment lasting longer than six months requires annual monitoring of specific laboratory parameters.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Orazole (Omeprazole) based on documented clinical presentation and required emergency procedures. In all cases of suspected over-exposure, patients should seek emergency medical attention immediately, or contact a Poison Help line.

Overdoses have been reported with doses up to 900 mg. Regulatory findings indicate that the reported symptoms are typically transient, and no serious clinical outcome has been associated with these documented cases of overdosage.

Documented Overdose Manifestations

The following clinical signs have been reported in cases of high exposure:

System Manifestations
Central Nervous System Confusion, Drowsiness, Headache, Blurred Vision
Autonomic/General Tachycardia, Nausea, Diaphoresis (Increased Sweating), Flushing, Dry Mouth

Required Emergency Management

Management is strictly procedural: treatment is required to be symptomatic and supportive. This approach is necessary because no specific antidote for Orazole overdosage is known. Official information notes that the active ingredient is extensively protein bound and therefore is not readily dialyzable.

Therapeutic Uses of Orazole

What Orazole Treats: Main Uses and Benefits

The core therapeutic application of Orazole is relevant for managing symptoms related to heightened physiological activity. This medication is commonly used to help manage symptomatic episodes and contributes to easing the overall symptom load associated with irritative states.

Orazole is commonly used across conditions presenting with acute episodes, such as Gastroesophageal Reflux Disease (GERD), and conditions involving inflammatory or irritative processes, including gastric and duodenal ulcers. It is also relevant as part of combination therapy to address H. pylori infection. It is applied within clinical settings that involve acute or unstable symptom patterns, such as conditions marked by increased physiological stress (e.g., Zollinger-Ellison Syndrome), and is used for managing conditions where symptoms may intensify temporarily, such as for prophylaxis (prevention) of ulcers during necessary long-term NSAID therapy.

The medication is used when groups of symptoms appear suddenly or fluctuate, such as frequent heartburn and acid regurgitation. It provides supportive relief when symptoms interfere with routine activities, and is applied in scenarios where additional management of discomfort is required.

Quick Fact: Relief for Chronic Heartburn
Orazole is considered relevant for easing symptoms that interfere with daily comfort and supports general well-being during symptomatic phases linked to the inner lining of the esophagus and stomach.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Orazole's eligibility for use is strictly defined by official regulatory documents to ensure population appropriateness.

Contraindicated Populations

The medicine is absolutely prohibited for the following populations:

  • Patients with known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation.
  • Patients concurrently receiving the antiviral agents rilpivirine or nelfinavir.
  • Individuals with rare metabolic disorders, such as galactose intolerance, Lapp Lactase deficiency, or glucose-galactose malabsorption, due to excipients in the oral formulation.

Age-Related Eligibility Rules

Age Group Eligibility Status
Adults Eligible for all labeled uses.
Pediatric ge 1 Year Eligible for symptomatic GERD and maintenance of healing.
Pediatric ge 1 Month Eligible for treatment of Erosive Esophagitis.
Infants <1 Month Use and effectiveness are not established.

Conditional Use and Restrictions

Use is conditional for patients with impaired hepatic function, where use is restricted and may require the application of a lower maximum daily dose. For patients with renal impairment or who are older adults, official labeling states that no specific dose adjustment is required. Use during pregnancy or lactation is generally acceptable but must be assessed, as use is permitted only when the clinical benefit justifies any potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Orazole has documented interactions with other medicines and products, which primarily stem from two mechanisms: the inhibition of the CYP2C19 liver enzyme and the effect on gastric pH.

Clinically Significant Interaction Categories

Mechanism / Interaction Type Interacting Product Classes Regulatory Constraint
Gastric pH-Dependent Absorption Antifungals (e.g., ketoconazole), Iron salts, Antivirals (e.g., atazanavir, nelfinavir) Can lead to reduced exposure and efficacy of the co-administered drug.
CYP2C19 Enzyme Inhibition Antiplatelet agents (e.g., clopidogrel), Benzodiazepines (e.g., diazepam), Anticoagulants (e.g., warfarin) Can lead to reduced activity of the co-administered drug (e.g., clopidogrel) or increased exposure/toxicity of the co-administered drug.
CYP Induction/Metabolism Strong CYP inducers (e.g., rifampin, St. John's wort) Can lead to a significant decrease in Orazole's systemic exposure.

Interaction-Related Restrictions

Certain combinations are subject to specific regulatory constraints:

  • Contraindicated Combinations: Co-administration with rilpivirine is contraindicated.
  • Avoid Concomitant Use: Concomitant use with atazanavir, nelfinavir, clopidogrel, rifampin, or St. John's wort is generally not recommended due to safety or efficacy concerns.
  • Monitoring Required: Co-administration with drugs like warfarin, tacrolimus, digoxin, and methotrexate may require enhanced monitoring or possible dose adjustment of the co-administered drug. Additionally, Orazole may interfere with diagnostic testing for neuroendocrine tumors by increasing Chromogranin A (CgA) levels, requiring temporary cessation before testing.

Mechanism of Action

How Orazole Works: Mechanism of Action

Orazole's action is defined by the irreversible blockade of the biological machinery responsible for producing acid in the stomach.

Irreversible Inactivation of the Gastric Proton Pump

This domain describes the drug's primary action: targeting the H^+ K^+-ATPase enzyme (the proton pump) in the stomach's acid-secreting cells. Orazole's active form creates a covalent, permanent bond with the enzyme, physically and irreversibly halting the final step of H^+ ion transport. This mechanism suppresses H^+ secretion regardless of the upstream physiological stimulus.

Activation and Sustained Physiological Effect

Orazole is a prodrug that requires activation by the acidic environment within the parietal cell, which limits the inhibitory action to the site of acid production. Because the enzyme is permanently disabled, the resulting sustained reduction in gastric acidity is maintained until the body can synthesize and insert entirely new, functional enzyme units into the cell membrane. The duration of this physiological effect is thus governed by the enzyme turnover rate, not the drug's systemic clearance.

Dosage and Administration Information

How to Use Orazole: Official Administration Guidelines

The usage of Orazole (omeprazole) is governed by specific instructions regarding administration route, timing, and dosage.

Administration Scope

Entity Instruction
Route of Administration Primarily oral (delayed-release capsules, tablets, or suspension), with an intravenous (IV) form available as an alternative when oral intake is inappropriate.
Dosing Schedule Most short-term regimens use 20 mg once daily. H. pylori eradication requires 20 mg twice daily as part of a combination therapy. For Pathological Hypersecretory Conditions, the initial dose is 60 mg once daily, with doses exceeding 80 mg administered in divided doses.
Timing in Relation to Meals Oral forms must be taken before a meal (e.g., before eating).
Special Procedural Conditions The enteric-coated capsule or tablet must be swallowed whole and must not be chewed or crushed. The capsule pellets may be mixed with a small amount of applesauce or a slightly acidic fluid if the patient is unable to swallow the solid form whole.

Population and Duration Rules

Classification Instruction
Duration Pattern Short-term treatment is typically 4 to 8 weeks. Long-term use is indicated for conditions like Pathological Hypersecretory Conditions and certain maintenance therapies.
Population Adjustments No dose adjustment is generally needed for the elderly or those with renal impairment. However, a dose of 10 mg to 20 mg may be sufficient for patients with hepatic impairment.
Missed Dose If a dose is missed, it should be taken as soon as remembered, but two doses should not be taken at the same time to compensate.

These official administration guidelines establish a standardized approach, ensuring the drug’s proper systemic delivery by defining frequency, dosing, and the necessary administration constraints.

Recent Clinical Evidence

Orazole's active ingredient, omeprazole, has been evaluated extensively through official clinical research to understand its evaluation for conditions related to excessive stomach acid. The findings, primarily derived from Randomized Controlled Trials (RCTs) and Meta-analyses, describe the evolution of symptom patterns and tissue response in different patient groups.

Research Evidence for Gastroesophageal Reflux Disease (GERD) and Esophagitis

Research has explored Orazole's use in people experiencing the outcomes related to physical discomfort of Gastroesophageal Reflux Disease (GERD), such as heartburn and acid regurgitation. Studies were conducted during periods of increased symptom activity and applied to populations including adults and some groups of pediatric patients. Researchers monitored patient-reported outcomes describing perceived discomfort over short treatment periods, typically 2 to 4 weeks. For Erosive Esophagitis (EE), trials explored the ability to achieve endoscopic healing and also studied its application over intermediate terms (up to 12 months) to explore the occurrence of recurrence of these lesions.

Studies on Ulcer Healing and Prevention of Recurrence

Research exploring outcomes related to Active Duodenal Ulcers and Active Benign Gastric Ulcers examined physical outcomes related to the healing rate of the ulcers during acute phases. Orazole was studied for H. pylori infection exclusively as part of a multi-drug combination regimen (with antibiotics). Systematic Reviews evaluated the rate of microbiological eradication achieved by the full combination regimen. Monotherapy (using the drug alone) was not evaluated for this purpose.

Research Gaps and Remaining Uncertainties

Several research limitation frames are recognized by scientists and regulators. Follow-up durations were limited in many pivotal efficacy trials, meaning long-term effects are not fully established. There is limited information for long-term outcomes related to continued use over many years. Also, some results apply only to the populations studied, and external validity is questioned because trial participants often had specific, non-complex profiles. Research is ongoing to address these gaps.

Key Studies & References Omeprazole: MedlinePlus Drug Information (Definition and Uses)

Frequently Asked Questions (FAQ)

Common questions about Orazole (FAQ)

Q: What is Orazole?

A: Orazole is the brand name for Omeprazole, a medication classified as a Proton Pump Inhibitor (PPI). It is approved to reduce the amount of acid produced by the stomach.

Q: What conditions is Orazole used for?

A: Orazole is approved for short-term and long-term treatment of certain conditions where excess stomach acid may be present. This includes:

  • Healing and maintenance of erosive esophagitis (damage to the esophagus from stomach acid).
  • Treating symptomatic Gastroesophageal Reflux Disease (GERD).
  • Treating and preventing the return of ulcers in the stomach and small intestine (gastric and duodenal ulcers).
  • Managing conditions where the stomach produces too much acid, such as Zollinger-Ellison Syndrome.
  • It may also be used in combination with certain antibiotics to help treat ulcers caused by H. pylori bacteria.

Q: What is the typical storage information for Orazole?

A: Orazole should be stored at room temperature away from excessive heat, moisture, and light. It is important to keep the medicine out of the sight and reach of children and pets.

How should Orazole be stored and disposed of?

How to Store and Dispose of Orazole?

Strict storage conditions are required for Omeprazole (Orazole) to maintain the integrity of its delayed-release formulation.

Storage Requirements

The medication must be stored at a temperature not exceeding 30°C and should be protected from light and moisture. The product must be kept in its original container and the container must remain tightly closed to preserve its stability. As a mandatory safety requirement, Orazole must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Omeprazole should be discarded through an official drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and thrown into the household trash, consistent with government guidelines. Omeprazole is not on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

flagNicaragua

Equivalent of Orazole found in:

A-Z Index: